Onkos Surgical® and 3D Systems Team to Advance Personalized Surgical Oncology Solutions
PARSIPPANY, New Jersey, March 6, 2018 – Onkos Surgical, Inc. announced today that it signed a 4-year agreement with 3D Systems (NYSE: DDD) to advance the delivery of personalized surgical solutions and help improve patient outcomes. The agreement provides Onkos Surgical priority access to 3D Systems’ VSP® (Virtual Surgical Planning) Orthopedic product line for surgical planning, as well as 3D printed anatomical models. Additionally, the companies will collaborate on next-generation 510(k) clearances for 3D printed implants and instruments for tumor reconstruction.
Through this partnership, the companies aim to advance the delivery of personalized surgical solutions to help improve outcomes for patients with tumors and lesions occurring in the pelvis and long bones (i.e., the large bones found in the arms and legs) associated with musculoskeletal cancers. The combination of VSP and 3D printing allows surgeons to preoperatively plan a surgical procedure, as well as design surgical tools and implants for each patient’s unique case.
Established by 3D Systems, VSP technology received FDA market clearance for the cranio-maxillofacial region as a service-based approach to personalized surgery, combining expertise in medical imaging, surgical simulation and 3D printing. The surgeon initiates the process, bringing their clinical knowledge and desired surgical plan to an online web meeting with a 3D Systems biomedical engineer to simulate and plan the surgical procedure. The outcome is a digital plan that is transferred to the operating room via accurate 3D printed patient-specific models, guides and templates.
“We are delighted to announce this partnership with 3D Systems, a true visionary and leader in medical device 3D printing and surgical planning,” said Patrick Treacy, co-founder and chief executive officer, Onkos Surgical. “As an early stage investor in Onkos, they understand the criticality of our connection to the customer, the unique challenges these surgeons and patients face and the tremendous opportunity we have to make a difference for these patients while building a high value and scalable business.”
Onkos Surgical was founded in 2015 to deliver high quality implants and instruments that meet the unique needs of musculoskeletal tumor patients. The company quickly embraced 3D printing as a technology that could address the particular needs of both the cancer patient, and the cancer surgeon. Onkos Surgical realized the profound impact they could make if they combined personalized 3D printed medical devices and instrumentation with patient-specific surgical simulation.
“When we launched our Precision Oncology initiative at MSTS 2017 in Denver, it was met with great enthusiasm from the surgeon community,” said Sean Curry, senior vice president of commercial operations, Onkos Surgical. “The relationship with 3D Systems enhances our capabilities with product bundles and patient-specific solutions that will deliver on our promise of bringing focus and dedication to this space.”
“3D Systems is pleased to partner with Onkos Surgical delivering adaptive tools designed to provide insights, processes and outcomes for musculoskeletal oncology cases,” said Kevin McAlea, executive vice president, general manager, Metals and Healthcare, 3D Systems. “The combination of VSP and 3D printing provides an advantage for surgeons to personalize the surgical plan, instruments and implants for each unique case.”
According to the NIH – National Cancer Institute (cancer.gov), there were 3,260 new primary bone cancer cases reported in 2017. In addition to chemotherapy and radiation, two common surgical options for musculoskeletal cancer patients are amputation and limb salvage. Through limb salvage, the surgeon removes the cancer and some healthy tissue with the goal of leaving the limb largely intact. The section of bone that was removed can be replaced either with a bone graft from the patient or another person, or with an internal prosthesis (i.e., implants) made of metal and other materials.
Certain statements made in this release that are not statements of historical or current facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. In many cases, forward looking statements can be identified by terms such as “believes,” “belief,” “expects,” “may,” “will,” “estimates,” “intends,” “anticipates” or “plans” or the negative of these terms or other comparable terminology. Forward-looking statements are based upon management’s beliefs, assumptions and current expectations and may include comments as to the company’s beliefs and expectations as to future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside the control of the company. The factors described under the headings “Forward-Looking Statements” and “Risk Factors” in the company’s periodic filings with the Securities and Exchange Commission, as well as other factors, could cause actual results to differ materially from those reflected or predicted in forward-looking statements. Although management believes that the expectations reflected in the forward-looking statements are reasonable, forward-looking statements are not, and should not be relied upon as a guarantee of future performance or results, nor will they necessarily prove to be accurate indications of the times at which such performance or results will be achieved. The forward-looking statements included are made only as the date of the statement. 3D Systems undertakes no obligation to update or review any forward-looking statements made by management or on its behalf, whether as a result of future developments, subsequent events or circumstances or otherwise.
About Onkos Surgical
Based in Parsippany, NJ., Onkos Surgical is a privately held surgical oncology company founded in 2015. Onkos Surgical believes surgical oncology deserves attention, focus and innovation. Through dedication and strategic partnerships, Onkos Surgical will advance surgical oncology solutions and advocate for and support the surgeons and caregivers that dedicate their lives to the surgical treatment of cancer. For more information, visit www.onkossurgical.com
About 3D Systems
3D Systems provides comprehensive 3D products and services, including 3D printers, print materials, on demand manufacturing services and digital design tools. Its ecosystem supports advanced applications from the product design shop to the factory floor to the operating room. 3D Systems’ precision healthcare capabilities include simulation, Virtual Surgical Planning, and printing of medical and dental devices as well as patient-specific surgical instruments. As the originator of 3D printing and a shaper of future 3D solutions, 3D Systems has spent its 30-year history enabling professionals and companies to optimize their designs, transform their workflows, bring innovative products to market and drive new business models. More information on the company is available at www.3dsystems.com.
- Onkos Surgical Announces Definitive Agreement to Acquire the JTS Extendible Prosthesis
- Onkos Surgical Raises $15 Million in Series C Funding
- Onkos Surgical Announces FDA 510(k) Clearance of its BioGrip® Modular Porous Collars, a First-of-Its-Kind Solution to Help Address Implant Loosening in Orthopaedic Oncology and Complex Revision Surgery